UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
| (Check
one): |
|
☒Form
10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR
☐ Form N-CSR |
| |
|
|
| |
|
For
Period Ended: |
December
31, 2025 |
| |
|
|
| |
|
☐
Transition Report on Form 10-K |
| |
|
|
| |
|
☐
Transition Report on Form 20-F |
| |
|
|
| |
|
☐
Transition Report on Form 11-K |
| |
|
|
| |
|
☐
Transition Report on Form 10-Q |
| |
|
|
| |
|
☐
Transition Report on Form N-SAR |
| |
|
|
| |
|
For
the Transition Period Ended: |
| |
Read
Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein. |
| |
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I — REGISTRANT INFORMATION
POLOMAR
HEALTH SERVICES, INC.
Full
Name of Registrant
Former
Name if Applicable
32866
US Hwy. 19 N
Address
of Principal Executive Office (Street and Number)
Palm
Harbor, FL 34684
City,
State and Zip Code
PART
II — RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate)
| ☒ |
(a) |
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
| |
|
| (b) |
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the
fifth calendar day following the prescribed due date; and |
| |
|
| (c) |
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART
III — NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report portion thereof, could not
be filed within the prescribed time period.
The
Registrant has been unable, without unreasonable effort or expense, to timely compile all information for the disclosures required to
be included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The Registrant expects to file the Annual
Report no later than the fifteenth calendar day following
the prescribed filing date.
| SEC
1344 (04-09) |
|
Persons
who are to respond to the collection of information contained in this form are not required to respond unless the form displays a
currently valid OMB control number. |
(Attach
extra Sheets if Needed)
PART
IV — OTHER INFORMATION
| (1) | Name
and telephone number of person to contact in regard to this notification |
| |
| Terrence
M. Tierney |
|
(727)
|
|
425-7575 |
| (Name) |
|
(Area
Code) |
|
(Telephone
Number) |
| (2) |
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If answer is no, identify report(s). |
| |
Yes
☒ No ☐ |
| |
|
| (3) |
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof? |
| |
Yes
☒ No ☐ |
| |
|
| |
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made. |
| |
|
| |
The
registrant operates Polomar Specialty Pharmacy, a State of Florida licensed retail compounding
pharmacy.
|
| |
|
| |
The
registrant had revenues of approximately $648,321 for the twelve months ended December 31, 2025, compared to $58,824 of revenue for
the twelve months ended December 31, 2024. The increase in revenues over the previous accounting period was primarily due to the
contractual obligations of the registrant’s marketing partners and customers, due to an increase in fulfillment of drug prescriptions. |
| |
|
| |
Operating
expenses, which consisted mainly of general and administrative expenses, increased to approximately $2,206,920 for the twelve months
ended December 31, 2025, from approximately $1,330,399 for the twelve months ended December 31, 2024. Operating expenses for the
twelve months ended December 31, 2025, consisted mainly of legal, audit and accounting fees associated with the registrant’s
SEC filings of approximately $192,130, payroll of approximately $466,342, consulting fees of $185,414 and interest expense of $150,841.
In comparison, the registrant’s operating expenses for the twelve months ended December 31, 2024, consisted mainly of legal
and accounting fees associated with the registrant’s SEC filings of approximately $189,675 and payroll of approximately $380,476. |
| |
|
| |
The
registrant recorded a net loss of approximately $1,941,860 for the twelve months ended December 31, 2025, as compared with a net
loss of approximately $1,305,962 for the twelve months ended December 31, 2024, as a result of the expenses incurred and insufficient
revenues generated during the period, as described further above. |
POLOMAR
HEALTH SERVICES, INC.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: |
April
1, 2026 |
By: |
/s/
Terrence M. Tierney |
| |
|
|
Terrence
M. Tierney |
| |
|
|
President
and CEO |